CLAIMS

1. Use of the compound:




or




,

in the manufacture of a medicament for treating or preventing a disease, disorder, or condition, wherein the disease, disorder, or condition is Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, dementia with Lewy Bodies, multi systems atrophy, Huntington's disease, frontotemporal lobar degeneration, mild cognitive impairment, corticobasal degeneration, progressive supra nuclear palsy, Rett Syndrome, peripheral degenerative disease, Aicardi-Goutières syndrome, lupus, rheumatoid arthritis, Sjogrens syndrome, multiple sclerosis, atherosclerosis, osteoarthritis, osteoporosis, macular degeneration, autism spectrum disorder (ADS), pulmonary fibrosis, schizophrenia, ataxia-telangiectasia, psoriasis, or Fanconi Anemia.

2. The use of claim 1, wherein the compound is:




.

3. The use of claim 1, wherein the compound is:




.

4. The use of any one of claims 1-3, wherein the disease, disorder, or condition is Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, dementia with Lewy Bodies, multi systems atrophy, Huntington's disease, frontotemporal lobar degeneration, mild

cognitive impairment, corticobasal degeneration, progressive supra nuclear palsy, Rett Syndrome, peripheral degenerative disease, or Aicardi-Goutières syndrome.

5. The use of any one of claims 1-3, wherein the disease, disorder, or condition is lupus, rheumatoid arthritis, Sjogrens syndrome, or multiple sclerosis.

6. The use of any one of claims 1-3, wherein the disease, disorder, or condition is Alzheimer's disease, Parkinson's disease, atherosclerosis, osteoarthritis, osteoporosis, rheumatoid arthritis, macular degeneration, or peripheral degenerative disease.

7. The use of any one of claims 1-3, wherein the disease, disorder, or condition is autism spectrum disorder (ADS), pulmonary fibrosis, or schizophrenia.

8. The use of any one of claims 1-3, wherein the disease, disorder, or condition is progressive supra nuclear palsy.

9. The use of any one of claims 1-3, wherein the disease, disorder, or condition is amyotrophic lateral sclerosis.

10. The use of any one of claims 1-3, wherein the disease, disorder, or condition is Aicardi-Goutières syndrome.

11. The use of any one of claims 1-3, wherein the disease, disorder, or condition is ataxia-telangiectasia.

12. The use of any one of claims 1-3, wherein the disease, disorder, or condition is macular degeneration, lupus, psoriasis, Fanconi Anemia, pulmonary fibrosis, or cardiovascular disease.

13. The use of any one of claims 1-12, wherein the compound is to be administered in combination with one or more optional therapeutic agents.